GlobeNewswire·May 19, 2026, 8:30 AM ET

Autonomix Medical, Inc. Granted U.S. Patent for Transvascular Monitoring and Treatment Systems with Real-Time Procedural Validation

Autonomix Medical, Inc. received U.S. Patent No. 12,544,131 from the USPTO on May 19, 2026, for systems enabling monitoring & treatment of tissues through lumen walls.
The patent strengthens the company's intellectual property portfolio covering transvascular & neuromodulation platform technologies for functional nerve assessment & adaptive therapy.
The granted patent allows catheter-based tools to sense nerve activity through vessel walls & objectively confirm effective treatment in real-time using electrophysiological signals.
The system supports closed-loop control to dynamically adjust stimulation or therapeutic energy delivery based on live feedback for data-driven procedural workflows.
Patent claims include multi-site electrophysiological sensing at target, secondary, & reference sites to improve signal quality & procedural confidence.
Autonomix's IP portfolio includes issued patents in the U.S. & key international jurisdictions with expirations extending into the late 2030s.
The company's investigational catheter-based platform targets nerve-targeted indications including pancreatic cancer pain, cardiology, hypertension, & chronic pain management.
The technology is currently not cleared for marketing in the United States & is described as a first-in-class platform for transvascular diagnosis & treatment of peripheral nervous system diseases.